This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Lin F , Ionescu-Ittu R , Pivneva I , Wynant W , Shi S , Wu EQ , Kwong WJ , Abraham JA
The Economic Burden of Tenosynovial Giant Cell Tumors Among Employed Workforce in the United States
J Occup Environ Med. 2021 Apr 1;63(4) :e197-e202
PMID: 33560066 URL: https://www.ncbi.nlm.nih.gov/pubmed/33560066
AbstractOBJECTIVE: To assess the economic burden of tenosynovial giant cell tumor (TGCT) among US employed workforce. METHODS: Patients with TGCT medical claims (N = 1,395) and matched controls (1:10) without TGCT claims (N = 13,950) were identified from the OptumHealth Care Solutions, Inc. database (01/01/1999-31/03/2017). Adjusted regression models were used to compare healthcare resource utilization, time lost from work and associated costs between cohorts. RESULTS: In patients with TGCT, the rates of inpatient admissions, emergency room visits, outpatient visits, and work loss days were 2.8, 1.5, 2.2, and 2.6 times those of matched controls, respectively (all p < 0.001). Total annual all-cause healthcare costs and work loss-related costs were $9,368 and $2,708 higher for TGCT patients than for matched controls, respectively (all p < 0.001). CONCLUSIONS: TGCT was associated with a significant healthcare and work loss burden on US employers.
Notes1536-5948 Lin, Feng Ionescu-Ittu, Raluca Pivneva, Irina Wynant, Willy Shi, Sherry Wu, Eric Kwong, Winghan J Abraham, John A Journal Article United States J Occup Environ Med. 2021 Apr 1;63(4):e197-e202. doi: 10.1097/JOM.0000000000002159.